Puma Biotech punts near $300 million on Takeda discard
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer | Business Wire
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma Biotechnology | Evaluate
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | The Motley Fool
Puma Biotechnology
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotech Surges, Defying Yellen
Here's Why Puma Biotechnology, Inc. (PBYI) is Down on Tuesday
Puma Biotechnology
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
Puma Biotechnology Careers | Wellfound (formerly AngelList Talent)
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Product Pipeline
Jon Mead - Vice President of FP&A - Puma Biotechnology, Inc. | LinkedIn
ADAPTING
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc.
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
